In rare disease and specialty pharma, launch is only the beginning. Sustained growth often depends on patient activation, HCP confidence, coordinated care pathways and engagement that evolves across the critical first year.
All articles:
Ten things you should know to be an effective Medical Affairs team in an evolving healthcare landscape
Medical Affairs teams are evolving into more strategic, insight-driven partners across the product lifecycle. This article explores ten key shifts shaping how teams can work more effectively, from integrated evidence generation and AI-enabled insight to omnichannel engagement and role-specific training.
Gene therapy: turning challenges into opportunities
Gene therapy offers huge potential—but also poses distinct communication challenges. At Cognite, we help clients overcome barriers like small HCP audiences and complex science with strategies that build trust, clarity and emotional connection. This article explores how to turn common challenges into powerful engagement opportunities.
Rare Disease Day and the power of transformation
Explore how the rare disease landscape continues to be transformed by innovations in science, drug development and connectivity.
First commercialisation in Europe: overcoming the challenges
Explore how biotechs can navigate their first commercialisation in Europe, overcoming market fragmentation, pharma giants, resource constraints and regulatory hurdles to achieve a successful launch.
Predictions for the rare disease landscape in 2034
In this report, we reveal industry predictions for the rare disease landscape in 2034 and explore key approaches that show great promise, including gene therapies, artificial intelligence, whole-genome screening and personalised treatment, before assessing what the top priorities should be over the next decade to improve patient care.
Empowering solutions in Medical Affairs
Unlock the full potential of Medical Affairs teams in the pharmaceutical industry to address complex challenges and lead strategic decision-making.
PROs: Can patients ‘co-develop’ their treatment?
Discover the value of patient-reported outcomes (PROs) in clinical trials and how they can help address unmet needs in ovarian cancer.
Harnessing AI to revolutionise clinical trials
Discover how digital twins and synthetic control arms can revolutionise drug development. Learn about their impact on precision medicine and patient outcomes.
How to measure the value of Medical Affairs teams
Discover how to redefine qualitative and quantitative metrics in Medical Affairs to improve patient outcomes whilst demonstrating value to the organisation.